Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne-Rauzy, Moshe Mittelman, Petra Muus, Stephen D Nimer, Eva Hellström-Lindberg, Bayard L. Powell, Agnes Guerci-Bresler, Mikkael A. Sekeres, H. Joachim Deeg, Consuelo Del Cañizo, Peter L. Greenberg, Jamile M. Shammo, Barry Skikne, Xujie Yu, Alan F. List

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods: We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results: A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks. Conclusions: Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. Trial registration: ClinicalTrials.gov NCT00065156 and NCT00179621

Original languageEnglish (US)
Article number131
JournalJournal of Hematology and Oncology
Volume10
Issue number1
DOIs
StatePublished - Jun 26 2017

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Age Groups
Erythrocyte Transfusion
Cytogenetics
Multicenter Studies
lenalidomide

Keywords

  • Acute myeloid leukemia
  • Age
  • del(5q)
  • Lenalidomide
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). / Fenaux, Pierre; Giagounidis, Aristoteles; Selleslag, Dominik; Beyne-Rauzy, Odile; Mittelman, Moshe; Muus, Petra; Nimer, Stephen D; Hellström-Lindberg, Eva; Powell, Bayard L.; Guerci-Bresler, Agnes; Sekeres, Mikkael A.; Deeg, H. Joachim; Del Cañizo, Consuelo; Greenberg, Peter L.; Shammo, Jamile M.; Skikne, Barry; Yu, Xujie; List, Alan F.

In: Journal of Hematology and Oncology, Vol. 10, No. 1, 131, 26.06.2017.

Research output: Contribution to journalArticle

Fenaux, P, Giagounidis, A, Selleslag, D, Beyne-Rauzy, O, Mittelman, M, Muus, P, Nimer, SD, Hellström-Lindberg, E, Powell, BL, Guerci-Bresler, A, Sekeres, MA, Deeg, HJ, Del Cañizo, C, Greenberg, PL, Shammo, JM, Skikne, B, Yu, X & List, AF 2017, 'Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)', Journal of Hematology and Oncology, vol. 10, no. 1, 131. https://doi.org/10.1186/s13045-017-0491-2
Fenaux, Pierre ; Giagounidis, Aristoteles ; Selleslag, Dominik ; Beyne-Rauzy, Odile ; Mittelman, Moshe ; Muus, Petra ; Nimer, Stephen D ; Hellström-Lindberg, Eva ; Powell, Bayard L. ; Guerci-Bresler, Agnes ; Sekeres, Mikkael A. ; Deeg, H. Joachim ; Del Cañizo, Consuelo ; Greenberg, Peter L. ; Shammo, Jamile M. ; Skikne, Barry ; Yu, Xujie ; List, Alan F. / Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). In: Journal of Hematology and Oncology. 2017 ; Vol. 10, No. 1.
@article{0dec7e1c558e41a2a99cdf937bc7834d,
title = "Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)",
abstract = "Background: Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods: We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results: A total of 33.9, 34.3, and 31.8{\%} patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks. Conclusions: Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. Trial registration: ClinicalTrials.gov NCT00065156 and NCT00179621",
keywords = "Acute myeloid leukemia, Age, del(5q), Lenalidomide, Myelodysplastic syndromes",
author = "Pierre Fenaux and Aristoteles Giagounidis and Dominik Selleslag and Odile Beyne-Rauzy and Moshe Mittelman and Petra Muus and Nimer, {Stephen D} and Eva Hellstr{\"o}m-Lindberg and Powell, {Bayard L.} and Agnes Guerci-Bresler and Sekeres, {Mikkael A.} and Deeg, {H. Joachim} and {Del Ca{\~n}izo}, Consuelo and Greenberg, {Peter L.} and Shammo, {Jamile M.} and Barry Skikne and Xujie Yu and List, {Alan F.}",
year = "2017",
month = "6",
day = "26",
doi = "10.1186/s13045-017-0491-2",
language = "English (US)",
volume = "10",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

AU - Fenaux, Pierre

AU - Giagounidis, Aristoteles

AU - Selleslag, Dominik

AU - Beyne-Rauzy, Odile

AU - Mittelman, Moshe

AU - Muus, Petra

AU - Nimer, Stephen D

AU - Hellström-Lindberg, Eva

AU - Powell, Bayard L.

AU - Guerci-Bresler, Agnes

AU - Sekeres, Mikkael A.

AU - Deeg, H. Joachim

AU - Del Cañizo, Consuelo

AU - Greenberg, Peter L.

AU - Shammo, Jamile M.

AU - Skikne, Barry

AU - Yu, Xujie

AU - List, Alan F.

PY - 2017/6/26

Y1 - 2017/6/26

N2 - Background: Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods: We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results: A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks. Conclusions: Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. Trial registration: ClinicalTrials.gov NCT00065156 and NCT00179621

AB - Background: Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods: We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results: A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks. Conclusions: Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. Trial registration: ClinicalTrials.gov NCT00065156 and NCT00179621

KW - Acute myeloid leukemia

KW - Age

KW - del(5q)

KW - Lenalidomide

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=85021334233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021334233&partnerID=8YFLogxK

U2 - 10.1186/s13045-017-0491-2

DO - 10.1186/s13045-017-0491-2

M3 - Article

C2 - 28651604

AN - SCOPUS:85021334233

VL - 10

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 131

ER -